Literature DB >> 11265922

Down syndrome: advances in molecular biology and the neurosciences.

G T Capone1.   

Abstract

The entire DNA sequence for human chromosome 21 is now complete, and it is predicted to contain only about 225 genes, which is approximately three-fold fewer than the number initially predicted just 10 years ago. Despite this remarkable achievement, very little is known about the mechanism(s) whereby increased gene copy number (gene dosage) results in the characteristic phenotype of Down syndrome. Although many of the phenotypic traits show large individual variation, neuromotor dysfunction and cognitive and language impairment are observed in virtually all individuals. Currently, there are no efficacious biomedical treatments for these central nervous system-associated impairments. To develop novel therapeutic strategies, the effects of gene dosage imbalance need to be understood within the framework of those critical biological events that regulate brain organization and function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11265922     DOI: 10.1097/00004703-200102000-00007

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  27 in total

1.  Detection of DNA copy number abnormality by microarray expression analysis.

Authors:  Xiaofeng Zhou; Steven W Cole; Shen Hu; David T W Wong
Journal:  Hum Genet       Date:  2004-02-11       Impact factor: 4.132

2.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.

Authors:  Jisook Moon; May Chen; Shruti U Gandhy; Myla Strawderman; David A Levitsky; Kenneth N Maclean; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

3.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

4.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

5.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

6.  CASP3 protein expression by flow cytometry in Down's syndrome subjects.

Authors:  Michele Salemi; Rosita A Condorelli; Corrado Romano; Barone Concetta; Carmelo Romano; Maria Grazia Salluzzo; Paolo Bosco; Aldo E Calogero
Journal:  Hum Cell       Date:  2013-12-13       Impact factor: 4.174

Review 7.  4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.

Authors:  Marzia Perluigi; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-15       Impact factor: 8.401

8.  Screening for autism spectrum disorders in children with Down syndrome: population prevalence and screening test characteristics.

Authors:  Carolyn DiGuiseppi; Susan Hepburn; Jonathan M Davis; Deborah J Fidler; Sara Hartway; Nancy Raitano Lee; Lisa Miller; Margaret Ruttenber; Cordelia Robinson
Journal:  J Dev Behav Pediatr       Date:  2010-04       Impact factor: 2.225

9.  Lack of association between down syndrome and polymorphisms in dopamine receptor D4 and serotonin transporter genes.

Authors:  Aneek Das Bhowmik; Samikshan Dutta; Swagata Sinha; Anindita Chattopadhyay; Kanchan Mukhopadhyay
Journal:  Neurochem Res       Date:  2008-02-13       Impact factor: 3.996

10.  KIF21A mRNA expression in patients with Down syndrome.

Authors:  Michele Salemi; Concetta Barone; Carmelo Romano; Federico Ridolfo; Cataldo Scavuzzo; Rita Anna Cantarella; Maria Grazia Salluzzo; Aldo E Calogero; Corrado Romano; Paolo Bosco
Journal:  Neurol Sci       Date:  2012-09-12       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.